138 related articles for article (PubMed ID: 37830319)
1. [Meningioma under progestin treatment : what attitude to adopt ?].
Cornu E; Pintiaux A; Reuter G; Kridelka F; Pétrossians P; Potorac I
Rev Med Liege; 2023 Oct; 78(10):550-557. PubMed ID: 37830319
[TBL] [Abstract][Full Text] [Related]
2. Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate - Monocentric ongoing study on progestin related meningiomas.
Devalckeneer A; Aboukais R; Bourgeois P; De Witte O; Racape J; Caron S; Perbet R; Maurage CA; Lejeune JP
Clin Neurol Neurosurg; 2021 Nov; 210():106959. PubMed ID: 34592677
[TBL] [Abstract][Full Text] [Related]
3. Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome.
Graillon T; Boissonneau S; Appay R; Boucekine M; Peyrière H; Meyer M; Farah K; Albarel F; Morange I; Castinetti F; Brue T; Fuentes S; Figarella-Branger D; Cuny T; Dufour H
Neurochirurgie; 2021 Nov; 67(6):556-563. PubMed ID: 33989642
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience.
Malaize H; Samoyeau T; Zanello M; Roux A; Benzakoun J; Peeters S; Zah-Bi G; Edjlali M; Tauziede-Espariat A; Dezamis E; Parraga E; Chrétien F; Varlet P; Plu-Bureau G; Oppenheim C; Pallud J
J Neurooncol; 2021 Apr; 152(2):279-288. PubMed ID: 33449307
[TBL] [Abstract][Full Text] [Related]
5. Meningioma in patients exposed to progestin drugs: results from a real-life screening program.
Samoyeau T; Provost C; Roux A; Legrand L; Dezamis E; Plu-Bureau G; Pallud J; Oppenheim C; Benzakoun J
J Neurooncol; 2022 Oct; 160(1):127-136. PubMed ID: 36066786
[TBL] [Abstract][Full Text] [Related]
6. Opposed evolution of the osseous and soft parts of progestin-associated osteomeningioma after progestin intake discontinuation.
Florea SM; Passeri T; Abbritti R; Bernat AL; Fontanel S; Yoldjian I; Funck-Brentano T; Weill A; Mandonnet E; Froelich S
J Neurosurg; 2023 Oct; 139(4):944-952. PubMed ID: 36883659
[TBL] [Abstract][Full Text] [Related]
7. Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas.
Apra C; Roblot P; Alkhayri A; Le Guérinel C; Polivka M; Chauvet D
J Neurooncol; 2020 Aug; 149(1):95-101. PubMed ID: 32705456
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and Progesterone Therapy and Meningiomas.
Hage M; Plesa O; Lemaire I; Raffin Sanson ML
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34935947
[TBL] [Abstract][Full Text] [Related]
9. Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.
Devalckeneer A; Aboukais R; Faisant M; Bourgeois P; Quentin VM; Maurage CA; Escande F; Lejeune JP
Neurosurg Rev; 2022 Apr; 45(2):1691-1699. PubMed ID: 34850321
[TBL] [Abstract][Full Text] [Related]
10. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.
Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J
BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184
[TBL] [Abstract][Full Text] [Related]
11. Dramatic Shrinkage with Reduced Vascularization of Large Meningiomas After Cessation of Progestin Treatment.
Kalamarides M; Peyre M
World Neurosurg; 2017 May; 101():814.e7-814.e10. PubMed ID: 28300711
[TBL] [Abstract][Full Text] [Related]
12. Risk of intracranial meningioma with three potent progestogens: A population-based case-control study.
Hoisnard L; Laanani M; Passeri T; Duranteau L; Coste J; Zureik M; Froelich S; Weill A
Eur J Neurol; 2022 Sep; 29(9):2801-2809. PubMed ID: 35621369
[TBL] [Abstract][Full Text] [Related]
13. Use of progestogens and the risk of intracranial meningioma: national case-control study.
Roland N; Neumann A; Hoisnard L; Duranteau L; Froelich S; Zureik M; Weill A
BMJ; 2024 Mar; 384():e078078. PubMed ID: 38537944
[TBL] [Abstract][Full Text] [Related]
14. Radiological evolution of progestogen-induced meningioma: A monocentric retrospective study.
Ahmed-Khalifa T; Gillet R; Blonski M; Rech F; Fresse A; Gillet P; Taillandier L; Petitpain N
Fundam Clin Pharmacol; 2023 Aug; 37(4):868-878. PubMed ID: 36692232
[TBL] [Abstract][Full Text] [Related]
15. Sustained growth of intraosseous hormone-associated meningiomas after cessation of progestin therapy.
AbiJaoude S; Marijon P; Roblot P; Tran S; Cornu P; Kalamarides M; Peyre M
Acta Neurochir (Wien); 2021 Jun; 163(6):1705-1710. PubMed ID: 33649877
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic progestin-associated atypical grade II meningioma. A first case report.
Roux A; Tauziede-Espariat A; Zanello M; Gareton A; Malaize H; Benzakoun J; Zah-Bi G; Oppenheim C; Plu-Bureau G; Chretien F; Pallud J
Neurochirurgie; 2020 Jun; 66(3):174-178. PubMed ID: 32277999
[TBL] [Abstract][Full Text] [Related]
17. First case of cyproterone acetate induced multiple meningiomas in identical female twins: A case report.
Batchinsky-Parrou V; Barraud S; Kleiber JC; Litre F
Neurochirurgie; 2022 Apr; 68(3):323-326. PubMed ID: 33989640
[TBL] [Abstract][Full Text] [Related]
18. Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report.
Champagne PO; Passeri T; Froelich S
Acta Neurochir (Wien); 2019 Mar; 161(3):589-592. PubMed ID: 30666456
[TBL] [Abstract][Full Text] [Related]
19. Progestin-associated shift of meningioma mutational landscape.
Peyre M; Gaillard S; de Marcellus C; Giry M; Bielle F; Villa C; Boch AL; Loiseau H; Baussart B; Cazabat L; Raffin-Sanson ML; Sanson M; Kalamarides M
Ann Oncol; 2018 Mar; 29(3):681-686. PubMed ID: 29206892
[TBL] [Abstract][Full Text] [Related]
20. Abrupt regression of a meningioma after discontinuation of cyproterone treatment.
Gonçalves AM; Page P; Domigo V; Méder JF; Oppenheim C
AJNR Am J Neuroradiol; 2010 Sep; 31(8):1504-5. PubMed ID: 20053802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
